ArticleJournal of clinical microbiology2020
Reduced
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 80 citations in OpenAlex.
- Inhibitors of GapN-dependent NADPH supply as potential lead compounds for novel therapeutics againstVirulence · 2026Article
- Tracing the recent evolution of Group AEmerging microbes & infections · 2026Review
- Clinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Review
- Identification ofAntimicrobial agents and chemotherapy · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.npj antimicrobials and resistance · 2026Article
- Molecular analysis of Lancefield group C/G streptococci causing human infections in Sheffield, UK.Microbial genomics · 2026Article
- Modelling the Effects of Treatment Failure on the Minor Outbreak Duration for Carrier-Related Infectious Disease.Epidemiologia (Basel, Switzerland) · 2026Article
- Evaluating the use of whole-genome sequencing and SangerJournal of medical microbiology · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.Research square · 2026Article
- Group A Streptococcal Virulence Factors and Vaccine Development-An Update.Microorganisms · 2026Review
- Antimicrobial resistance of Group A Streptococcus isolates from patients in Shenzhen, China during COVID-19 pandemic.BMC pediatrics · 2026Article
- Penicillin-Binding Proteins inAntibiotics (Basel, Switzerland) · 2026Review
- Targeting Streptococcus pyogenes atpF protein for multi-epitope vaccine development: a genomics-driven immunoinformatics strategy.Journal, genetic engineering & biotechnology · 2025Article
- Evaluation of Peptide-Based Vaccines AgainstVaccines · 2025Article
- Prevalence and emm typing of multi-drug resistant Streptococcus pyogenes in tertiary care health settings.BMC microbiology · 2025Article
- Article
- Analysis of ESAC-Net/EARS-Net Data from 29 EEA Countries for Spatiotemporal Associations Between Antimicrobial Use and Resistance-Implications for Antimicrobial Stewardship?Antibiotics (Basel, Switzerland) · 2025Article
- Genomic interrogation of invasive group AThe Lancet regional health. Western Pacific · 2025Article
- Global spread of Streptococcus pyogenes A genomics-supported narrative review.FEMS microbiology reviews · 2025Review
- The intricate pathogenicity of Group AVirulence · 2024Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 7 countries.
James M Musser *Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA jmmusser@houstonmethodist.org.
Stephen B Beres *Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA.
Luchang Zhu *Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA.
Randall J Olsen *Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA.
Jaana VuopioInstitute of Biomedicine, University of Turku, Turku, Finland.
Hanne-Leena HyyryläinenDepartment of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
Kirsi Gröndahl-Yli-HannukselaInstitute of Biomedicine, University of Turku, Turku, Finland.
Karl G KristinssonDepartment of Clinical Microbiology, Landspitali University Hospital, Reykjavik, Iceland.
Jessica DarenbergPublic Health Agency of Sweden, Solna, Sweden.
Birgitta Henriques-NormarkDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Steen HoffmannNeisseria and Streptococcus Reference Laboratory, Bacteria, Parasites & Fungi, Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
Dominque A CaugantDivision for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Andrew J SmithCollege of Medical, Veterinary and Life Sciences, Glasgow Dental Hospital and School, University of Glasgow, Glasgow, Scotland.
Diane S J LindsayScottish Microbiology Reference Laboratory, Glasgow, Scotland.
David M BoragineDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Timothy PalzkillDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-5267-0001
Houston Methodist · USBaylor College of Medicine · USUniversity of Turku · FIFinnish Institute for Health and Welfare · FIKarolinska University Hospital · SENorwegian Institute of Public Health · NOPublic Health Agency of Sweden · SEReykjavík University · ISStatens Serum Institut · DKUniversity of Glasgow · GB
Funding
HOUSTON AREA MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008280 · NIGMS · RICE UNIVERSITY · PI WENSEL, THEODORE G · 1988 to 2023
$8.0MBETA-LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCER01AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI Timothy Palzkill · 1992 to 2026
$6.5MBeta Lactamase Mutations in Antibiotic ResistanceR37AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2001 to 2010
$3.3MDeterminants of Streptococcus pyogenes virulence in the primate oropharynx: A genome-wide analysisR21AI139369 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MUSSER, JAMES MALLORY · 2019 to 2020
$444kDeterminants of Streptococcus pyogenes fitness in the female primate genital tract: A genome-wide analysisR21AI146771 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MUSSER, JAMES MALLORY · 2019 to 2020
$444kBeta Lactamase Mutations in Antibiotic ResistanceR56AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2016 to 2016
$394kNIAID NIH HHS R01 AI032956NIAID NIH HHS R21 AI139369NIAID NIH HHS R21 AI146771NIAID NIH HHS R37 AI032956NIAID NIH HHS R56 AI032956NIGMS NIH HHS T32 GM008280
Abstract
Recently, two related
Indexed as
beta-LactamsStreptococcus pyogenesAnti-Bacterial AgentsBacterial ProteinsHumansMicrobial Sensitivity TestsMutationPenicillin-Binding ProteinsPhylogenyAnti-Bacterial AgentsBacterial Proteinsbeta-LactamsPenicillin-Binding Proteinsantibiotic resistancebioinformaticspopulation genomicspublic healthwhole-genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.